Kane Biotech Announces New Agreement with OTBC
WINNIPEG, Manitoba -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) has recently taken a significant step forward by entering a new service agreement with Outside the Box Capital Inc. (OTBC). This change signals Kane Biotech's commitment to strengthening its communications with the financial community. The announcement marks the end of the previously established service agreement that was initiated earlier in the year.
New Marketing Agreement Details
The previous service agreement was terminated to align with the updated policies of the TSX Venture Exchange, which now restrict the issuance of shares as compensation for investor relations services. As a result, Kane Biotech and OTBC have structured a new service agreement that financially supports their collaborative efforts.
Compensation Structure
Under the new contractual terms, OTBC will receive a cash payment of $100,000. This amount will be distributed in quarterly installments over a 12-month period. In addition, they will also be granted an option to purchase 1,000,000 shares at an exercise price of $0.10 per share, a strategy designed to benefit both parties as they work to enhance Kane Biotech’s market presence.
Expanding Marketing Efforts
The marketing services provided by OTBC will include a variety of digital marketing strategies across social media platforms. This initiative aims to broaden awareness regarding Kane Biotech and its innovative technologies, which focus on preventing and eliminating microbial biofilms. Kane aims to reach a wider audience within the financial community, thereby boosting investor engagement and visibility.
About Kane Biotech
Kane Biotech Inc. is dedicated to the research and development of cutting-edge technologies that address microbial biofilms. With a robust portfolio that includes 65 patents and proprietary products, Kane continues to leverage its expertise in biofilm research. The company’s well-known products, including DispersinB® and coactiv+™, highlight their continual innovation within the biotechnology industry.
Future Prospects
Kane Biotech's new partnership with OTBC reflects a proactive approach to adapting to market conditions and regulatory changes. Collaboration with OTBC is expected to enhance their outreach, making it easier to connect with potential investors and industry stakeholders. As Kane Biotech looks ahead, the focus will remain on expanding its reach while emphasizing the importance of strategic partnerships in achieving its objectives.
Contact Information
For further inquiries, interested parties can reach out to:
Marc Edwards
Chief Executive Officer
Kane Biotech Inc.
Email: medwards@kanebiotech.com
Ray Dupuis
Chief Financial Officer
Kane Biotech Inc.
Email: rdupuis@kanebiotech.com
Frequently Asked Questions
What is the purpose of the new agreement with OTBC?
The new agreement focuses on enhancing Kane Biotech's marketing efforts to effectively communicate with the financial community.
How much will OTBC be compensated under the new agreement?
OTBC will receive a total of $100,000 in cash, payable in quarterly installments over a year.
What are the main products developed by Kane Biotech?
Kane Biotech specializes in preventing and removing microbial biofilms and has notable products such as DispersinB® and coactiv+™.
Why was the previous agreement terminated?
The termination followed changes in the policies of the TSX Venture Exchange, restricting the issuance of shares for investor relations services.
What is Kane Biotech's strategy moving forward?
Moving forward, Kane Biotech plans to leverage their partnership with OTBC to enhance investor engagement and broaden market awareness.
